Curated News
By: NewsRamp Editorial Staff
March 13, 2025
United Health Products Updates Regulatory and Capital Markets Activities
Discuss on Reddit
LinkedIn
Substack
Telegram
GithubTLDR
- UHP's submission to OTCQB market aims to attract more investors and enhance trading liquidity, potentially giving a competitive advantage.
- UHP raised funds for clinical activities, submitted applications to OTC Markets and FDA, and negotiated a Clinical Trial Agreement with a hospital.
- UHP's CelluSTAT could revolutionize surgical procedures by controlling bleeding naturally, potentially improving patient outcomes and reducing complications.
- UHP's innovative hemostatic agent, CelluSTAT, could transform the medical field with its all-natural approach to controlling bleeding.
Impact - Why it Matters
This news matters as it provides insights into UHP's progress towards accessing the human surgical market with its hemostatic agent. The updates on regulatory approvals and capital funding indicate significant advancements in the company's development and potential market entry.
Summary
United Health Products, Inc. provided an update on its regulatory and capital markets activities, including an application to have its common shares quoted on the OTCQB market. The company raised over $500,000 through private placements to fund clinical activities related to its Premarket Approval application.
As part of the PMA process, UHP submitted an Investigational Device Exemption application to the FDA and completed negotiations for a Clinical Trial Agreement with a national hospital. Despite federal workforce reductions, the FDA response times to UHP's correspondence have been consistent.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, United Health Products Updates Regulatory and Capital Markets Activities
